期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

华法林治疗高龄非瓣膜性心房纤颤患者的临床观察 被引量：5

下载PDF
导出
摘要 目的评估华法林治疗高龄非瓣膜性心房纤颤(NVAF)患者的有效性及安全性。方法高龄NVAF住院及门诊随访患者193例,分为华法林组(112例)和阿司匹林组(81例)进行抗血栓治疗,平均随访(30.0±4.1)月,监测并比较两组患者血栓栓塞事件、出血事件的发生情况及风险。结果 193例中,共发生血栓栓塞事件14例,其中阿司匹林组11例,华法林组3例,两组差异有统计学意义(P<0.01);出血事件9例,其中华法林组8例,阿司匹林组1例,两组差异无统计学意义(P>0.05)。用CHADS2评分系统进行比较,栓塞风险评分越高栓塞发生率越高;且在血栓栓塞风险CHADS2或CHA2DS2-VAS评分系统各自分值≥3分时,阿司匹林组的栓塞风险明显增加(P<0.01或0.05)。结论对于高龄NVAF患者,华法林预防血栓栓塞事件的效果优于阿司匹林;高血栓栓塞风险(≥3分)的高龄NVAF患者,使用华法林会获益更多。
作者 吴雪婷 万惠青 丁少波 卫展扬
机构地区 广东省东莞市人民医院药剂科 广东省东莞市人民医院心血管内科
出处 《广东医学院学报》 2013年第5期569-570,共2页 Journal of Guangdong Medical College
关键词 心房颤动 华法林 阿司匹林 栓塞 卒中 危险评分
分类号 R541.75 [医药卫生—心血管疾病]
  • 相关文献

参考文献6

  • 1李斌,钟志雄.低抗凝强度华法林预防非瓣膜病心房颤动伴血栓危险因素患者栓塞事件的临床观察[J].广东医学院学报,2005,23(3):273-274. 被引量：3
  • 2程文俊,席建军.老年心房颤动抗凝治疗的现状与进展[J].中华老年心脑血管病杂志,2009,11(7):554-555. 被引量：7
  • 3Hylek E M,Skates S J,Sheehan M A. An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with nonrheumatic atrial fibrillation[J].New England Journal of Medicine,1996,(08):540-546.
  • 4Fang M C,Chang Y,Hylek E M. Advanced age,anticoagulation intensity,and risk for intracranial hemorrh-age among patients taking warfarin for atrial fibrillation[J].Annals of Internal Medicine,2004,(10):745-752.
  • 5Fuster V,Ryd6n L E,Cannom D S. ACC/AHA/ESC 2006guidelines for the management of patients with atrial fibrillation[J].Circulation,2006,(07):651-745.
  • 6Camm A J,Kirehhof P,Lip G Y. Guidelines for the management of atrial fibrillation[J].European Heart Journal,2010,(19):2369.

二级参考文献19

  • 1胡大一.心房颤动导管消融治疗的适应证:应从严掌握[J].心血管病学进展,2006,27(1):1-3. 被引量：13
  • 2黄维义,李刚,严丽,彭永权,罗兴林.华法林在慢性心房颤动抗凝治疗中的应用[J].临床心血管病杂志,2006,22(5):276-278. 被引量：24
  • 3黄从新,马长生,杨延宗,黄德嘉,张澍,江洪,杨新春,吴书林,马坚,刘少稳,李莉,曹克将,王方正,陈新.心房颤动：目前的认识和治疗建议(二)[J].中华心律失常学杂志,2006,10(3):167-197. 被引量：269
  • 4马长生.老年心房颤动患者的华法林抗凝治疗[J].中华老年心脑血管病杂志,2006,8(10):649-651. 被引量：25
  • 5刘岁丰,蹇在金.心房颤动抗凝治疗的现状与进展[J].中国老年学杂志,2007,27(9):910-911. 被引量：7
  • 6Heeringa J,van der Kuip DAM,Hofman A,et al.Prevalence,incidence and lifetime risk of atrial fibrillation:the Rotterdam study.Eur Heart J,2006,27:949-953.
  • 7Fuster V,Ryden LE,Cannom DS,et al.ACC/AHA/ESC 2006 guidelines for the manegment of patients with atrial fibrillation,full text a report of the American Colllege of Cardialogey/American Heart Association Task Force on carry out guidelines and the European Society of Cardialogy Committee for Practice Guidelines developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society.Europace,2006,8:651-745.
  • 8Mant J,Hobbs FDR,Fletcher K.Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation(the Bimingham Atrial Fibrillation Treatment of the Aged Study,BAFTA):a randomised controlled trial,Lancet,2007,370:493-503.
  • 9ACTIVE WritingGroup on behalf of the ACTIVE Investigators.Clopidogrel plus aspirin versus oral anticoagulation for atrial fibril|ation in the Atrial Fibrillation Ciopidogrel Trial with Irbesartan for Prevention of Vascular Events:a random ised cont rolled trial.Lancet,2006,367:1903-1912.
  • 10Boos CJ,Lip GY.Ximelagatran:a eubgy.Thromb Res,2006,118:301-304.

共引文献8

同被引文献35

  • 1张陶莉,张春晓.厄贝沙坦联合胺碘酮治疗老年慢性心力衰竭并阵发性心房纤颤临床观察[J].中华临床医师杂志（电子版）,2011,5(24):7425-7426. 被引量：12
  • 2Adams H P, Bendixen B H, Kappelle L, et al. Classi-fication of subtype of acute ischemic stroke. Defini-tion for use in a multicenter clinical trail. TOAST. Trial of Org 10172 in Acute Stroke Treatment[J]. Stroke, 1993, 24(1): 35-41.
  • 3Saposnik G, Gladstone D, Raptis R, et al. Atrial fi-brillation in ischemic stroke: predicting response to thrombolysis and clinical outcomes[J]. Stroke, 2013, 44(1): 99-104.
  • 4Poppe A Y, Majumdar S R, Jeerakathil T, et al. Admission hyperglycemia predicts a worse outcome in stroke patients treated with intravenous throm-bolysis[J]. Diabetes Care, 2009, 32(4): 617-622.
  • 5Murphy N F,Simpson C R,Jhund P S,et al.A national survey of the prevalence,incidence,primary care burden and treatment of atrial fibrillation in Scotland[J].Heart,2007,93(5):606-612.
  • 6Fuster V,Rydén L E,Cannom D S,et al.ACC/AHA/ESC 2006 Guidelines for the management of patients with atrial fibrillation:a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the European Society of Cardiology Committee for Practice Guidelines(Writing Committee to Revise the 2001guidelines for the management of patients with atrial fibrillation)developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society[J].Europace,2006,8(9):651-745.
  • 7Frost L,Engholm G,Johnsen S,et al.Incident stroke after discharge from the hosp ital with a diagnosis of atrial fibrillation[J].Am J Med,2000,108(1):36-40.
  • 8Pisters R,Lane D A,Nieuwlaat R,et al.A novel userfriendly score(HAS-BLED)to assess 1-year risk of major bleeding in patients with atrial fibrillation:the Euro Heart Survey[J].Chest,2010,138(5):1093-1100.
  • 9Camm A J,Lip G Y,De Caterina R,et al.2012focused update of the ESC Guidelines for the management of atrial fibrillation:an update of the 2010 ESC Guidelines for the mana gement of atrial fibrillation developed with the special contribution of the European HeartRhythm Association[J].Europace,2012,14(10):1385-1413.
  • 10ACTIVE Investigatiors,Connolly S J,Pogue J,et al.Effect of clopidogrel added to aspirin in patients with atrial fibrillation[J].N Engl J Med,2009,360(20):2066-2078.

引证文献5

二级引证文献1

广东医学院学报
2013年 第5期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部